CardioKinetix has developed a novel transcatheter implant called the Parachute Ventricular Partitioning Device (Parachute). The Parachute is designed to be a catheter-based partitioning device deployed within the left ventricle for patients who have developed ischemic left sided heart failure following a heart attack. The Parachute implant partitions the damaged muscle, isolating the non-functional muscle segment from the functional segment, which decreases the overall volume and restores a more normal geometry and function in the left ventricle.
|HQ||Menlo Park, US|
|Size (employees)||21 (est)|
CardioKinetix total Funding
CardioKinetix latest funding size
Time since last funding
|4 years ago|
|Cutlass Capital, Lexington Partners, Edwards Lifesciences, Panorama Capital, SV Health Investors, New Leaf Venture Partners|
When was CardioKinetix founded?
CardioKinetix was founded in 2003.
Who are CardioKinetix key executives?
CardioKinetix's key executives are Maria Sainz, Brett Hale and Bob Nicholas.
How many employees does CardioKinetix have?
CardioKinetix has 21 employees.
Who are CardioKinetix competitors?
Competitors of CardioKinetix include Pressure BioSciences, K2M Group and ResMed.
Where is CardioKinetix headquarters?
CardioKinetix headquarters is located at 1360 O'Brien Dr, Menlo Park.
Where are CardioKinetix offices?
CardioKinetix has an office in Menlo Park.
How many offices does CardioKinetix have?
CardioKinetix has 1 office.